Last reviewed · How we verify
NCT07433387
Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals
Phase 1, PHASE2 trial testing LP-98 20 mg in HIV in 30 participants. Currently enrolling.
10 July 2026
Quick facts
| Lead sponsor | Shanxi Kangbao Biological Product Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 29 January 2026 |
| Primary completion | 10 July 2026 |
| Estimated completion | 25 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- LP-98 20 mg — full drug profile →
- LP-98 40 mg — full drug profile →
- LP-98 80 mg — full drug profile →
Conditions studied
- HIV — all drugs for HIV →
Sponsor
Shanxi Kangbao Biological Product Co., Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07433387
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV
Currently open trials in the same condition.
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
- NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
- NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
- NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting
Other Shanxi Kangbao Biological Product Co., Ltd. trials
Trials by the same sponsor.
- NCT06560489 — Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients · Phase 1, PHASE2 · completed
- NCT06061536 — Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients. · Phase 2 · completed
- NCT05933824 — Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects · Phase 1 · completed
- NCT05349968 — Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients · Phase 1 · completed
- NCT04592315 — A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lipovirtide in HIV-infected Patients · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07433387 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanxi Kangbao Biological Product Co., Ltd.
- Last refreshed: 25 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07433387.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing